Mylan Pharmaceuticals has received approval to market two Parkinson’s disease generics, Carbidopa and Levodopa, in the US.

Mylan Pharmaceuticals, a subsidiary of Mylan, received approval from the US Food and Drug Administration for the treatments, the generic versions of Bristol Myers Squibb’s Parkinson’s treatment Sinemet.

The generic versions of Sinemet will be available as 10mg/100mg, 25mg/100mg and 25mg/250mg tablets.